Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

Science. 1996 Nov 22;274(5291):1363-6. doi: 10.1126/science.274.5291.1363.

Abstract

Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (FasL). In metastatic lesions, Fas-expressing T cell infiltrates were proximal to FasL+ tumor cells. In vitro, apoptosis of Fas-sensitive target cells occurred upon incubation with melanoma tumor cells; and in vivo, injection of FasL+ mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas-deficient lpr mutant mice in which immune effector cells cannot be killed by FasL. Thus, FasL may contribute to the immune privilege of tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis*
  • Fas Ligand Protein
  • Humans
  • Ligands
  • Lymphocytes, Tumor-Infiltrating / cytology
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Melanoma / immunology*
  • Melanoma / metabolism
  • Melanoma / pathology
  • Melanoma / secondary
  • Membrane Glycoproteins / analysis
  • Membrane Glycoproteins / biosynthesis
  • Membrane Glycoproteins / physiology*
  • Mice
  • Mice, Inbred C57BL
  • T-Lymphocytes, Cytotoxic / cytology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Tumor Cells, Cultured
  • Tumor Escape*
  • fas Receptor / biosynthesis
  • fas Receptor / physiology*

Substances

  • FASLG protein, human
  • Fas Ligand Protein
  • Fasl protein, mouse
  • Ligands
  • Membrane Glycoproteins
  • fas Receptor